Fractyl Health at Morgan Stanley conference: revita nears key data
Fractyl Health presented its Revita therapy at the Morgan Stanley 24th Annual Global Healthcare Conference, highlighting its potential to address the post-GLP-1 weight maintenance challenge. The company's leader, Harith Rajagopalan, emphasized that Revita aims to be the first therapeutic option for durable weight maintenance in obesity and type 2 diabetes, following the weight loss induced by GLP-1 drugs.
Fractyl estimates a significant market of roughly 1 million Americans who discontinue GLP-1 therapy each month, creating an opportunity for Revita's outpatient endoscopic procedure, which aims to restore normal nutrient signaling through a single intervention.
Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
